title: Should 3,4-dihydroxy-L-phenylalanine be used routinely in vascular Parkinson?
authors.forename: Fulvio
authors.initials: F
authors.lastname: Lauretani
authors.forename: Marcello
authors.initials: M
authors.lastname: Maggio
authors.forename: Anna
authors.initials: A
authors.lastname: Nardelli
authors.forename: Marsilio
authors.initials: M
authors.lastname: Saccavini
authors.forename: Gianpaolo
authors.initials: G
authors.lastname: Ceda
mesh_terms: D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D020734:Parkinsonian Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy*; D049268:Positron-Emission Tomography; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa